Skye Bioscience, Inc.
SKYE· Nasdaq
SKYESkye Bioscience, Inc.
Filed Aug 14, 2026 · 10-Q · 45 days after period end · 0001628280-26-056968
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Net Income | -$10.79M | -$17.62M | -$7.90M | -$3.11M |
| EPS Diluted | -$0.27 | -$0.44 | -$0.20 | -$0.80 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Skye Bioscience, Inc. · CIK 1516551 · Engraved from SEC EDGAR
ended Jun 30, 2026 · filed Aug 14, 2026 · 45 d after period end
